Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma

Summary

The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as adjuvant immunotherapy.

Timeline

Start

2020-10-26

Primary completion

2027-04-01

Completion

2030-04-30

Drugs

Indications